DR. MOUSREE GAYEN

DR. SNEHA JAIN, DR. NISHA BURA, DR. OISHWARYA CHAKRABORTY

Abstract

Purpose- To examine the effectiveness of Intravitreal biosimilar Ranibizumab injection (Injection RanizuRel) in the management of APROP.

Methods- This is a retrospective pilot study conducted over 1 year in which 50 eyes with APROP were chosen from outdoor and SNCU among 28 infants. Each of the eyes received 0.01 mg/0.1 ml of Injection RanizuRel aseptically in presence of Paediatrician. They were examined weekly and followed up upto the age of 6 months of age.

Results- 14 out of 50 eyes(28%) showed regressing APROP without having staging or plus disease and did not require laser therapy. 32 eyes out of 50(64%) needed laser photo coagulation in the avascular zone 2 and/or 3 after 50 weeks of age. 4 eyes(8%) showed reactivation after 3-4 weeks of injection and needed laser therapy in the avascular zone.

Conclusion- Although most of the patients required laser photocoagulation therapy but by the age of 6 months all the babies showed satisfactory results by reducing risk of progression.